Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Novo Nordisk ( (NVO) ).
Novo Nordisk reported a 12% increase in sales in Danish kroner and a 15% rise at constant exchange rates (CER) for the first nine months of 2025. Despite a 5% increase in operating profit, the company faced one-off restructuring costs of approximately DKK 9 billion, which impacted its profit growth. Novo Nordisk’s diabetes and obesity care segments showed significant growth, with obesity care sales rising by 37% in Danish kroner. The company also made strategic advancements in its R&D pipeline, including FDA approval for Wegovy® for MASH treatment and the acquisition of Akero Therapeutics. However, the company narrowed its full-year 2025 sales and operating profit growth expectations due to lower growth forecasts for its GLP-1 treatments. Additionally, Novo Nordisk announced an extraordinary general meeting to elect new board members on November 14, 2025.
The most recent analyst rating on (NVO) stock is a Hold with a $55.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.
Novo Nordisk’s overall stock score is driven by strong financial performance and attractive valuation. However, technical analysis indicates bearish momentum, and the earnings call revealed challenges in the U.S. market that could impact future growth. Despite these concerns, the company’s strategic focus on R&D and international expansion supports a positive long-term outlook.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company based in Denmark, specializing in diabetes care, obesity care, and rare diseases. The company is known for its innovative research and development pipeline, focusing on GLP-1 diabetes treatments and obesity management solutions.
Average Trading Volume: 15,152,435
Technical Sentiment Signal: Sell
Current Market Cap: $215.3B
For an in-depth examination of NVO stock, go to TipRanks’ Overview page.